These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 7056841)

  • 41. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
    Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
    Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
    Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases.
    Shen F-H ; Baylink DJ; Sherrard DJ; Shen L; Maloney NA; Wergedal JE
    J Clin Endocrinol Metab; 1975 Jun; 40(6):1009-17. PubMed ID: 1133150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome.
    Norris KC; Crooks PW; Nebeker HG; Hercz G; Milliner DS; Gerszi K; Slatopolsky E; Andress DL; Sherrard DJ; Coburn JW
    Am J Kidney Dis; 1985 Nov; 6(5):342-7. PubMed ID: 4061454
    [No Abstract]   [Full Text] [Related]  

  • 45. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining.
    Hodsman AB; Steer BM
    J Am Soc Nephrol; 1992 Feb; 2(8):1318-27. PubMed ID: 1378308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.
    Mathias R; Salusky I; Harman W; Paredes A; Emans J; Segre G; Goodman W
    J Am Soc Nephrol; 1993 Jun; 3(12):1938-46. PubMed ID: 8338926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low rate of bone formation with or without histologic appearance of osteomalacia in patients with aluminum intoxication.
    Charhon SA; Chavassieux PM; Chapuy MC; Boivin GY; Meunier PJ
    J Lab Clin Med; 1985 Aug; 106(2):123-31. PubMed ID: 2410522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of systemic aluminum on the resolution of a uremic and dietary phosphorus-dependent model of uremic osteomalacia in rats.
    Lieuallen WG; Weisbrode SE
    J Bone Miner Res; 1991 Jul; 6(7):751-7. PubMed ID: 1950679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy.
    Karsenty G; Vigneron N; Jorgetti V; Fauchet M; Zingraff J; Drüeke T; Cournot-Witmer G
    Kidney Int; 1986 May; 29(5):1058-65. PubMed ID: 3723927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dialysis osteomalacia: clinical aspects and physiopathological mechanisms.
    Drüeke T; Cournot-Witmer G
    Clin Nephrol; 1985; 24 Suppl 1():S26-9. PubMed ID: 3915957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone metabolism in chronic renal failure.
    Evans RA; Flynn J; Dunstan CR; George CR; McDonnell GD
    Miner Electrolyte Metab; 1982 Apr; 7(4):207-18. PubMed ID: 7169987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD.
    Salusky IB; Coburn JW; Brill J; Foley J; Slatopolsky E; Fine RN; Goodman WG
    Kidney Int; 1988 May; 33(5):975-82. PubMed ID: 3392886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal osteodystrophy.
    Coburn JW; Henry DA
    Adv Intern Med; 1984; 30():387-424. PubMed ID: 6397042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
    Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
    Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxalosis associated with aluminum bone disease: a new type of mixed renal osteodystrophy.
    Krpan D; Milutinovic S; Nikolic V; Tomicic D; Lajtman Z; Prot F
    Nephron; 1994; 66(1):99-101. PubMed ID: 8107962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dialysis osteomalacia and aluminum toxicity: a form of renal osteodystrophy.
    Felsenfeld AJ
    ANNA J; 1985 Jun; 12(3):189-91. PubMed ID: 3848318
    [No Abstract]   [Full Text] [Related]  

  • 57. Significance of minimodeling in dialysis patients with adynamic bone disease.
    Ubara Y; Tagami T; Nakanishi S; Sawa N; Hoshino J; Suwabe T; Katori H; Takemoto F; Hara S; Takaichi K
    Kidney Int; 2005 Aug; 68(2):833-9. PubMed ID: 16014063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.
    Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ
    Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of bone disease in the dialysis patient.
    Crooks PW; Coburn JW
    Blood Purif; 1985; 3(1-3):27-41. PubMed ID: 3913448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Changes of PTH, 1,25(OH)2D3 and biochemistry in renal osteodystrophy].
    Jia JK; Lou DX; Zhu P
    Zhonghua Nei Ke Za Zhi; 1994 Jan; 33(1):33-6. PubMed ID: 8045186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.